Read More Pharma Industry News OSR Holdings (NASDAQ: OSRH) explores royalty-driven licensing for Vaximm’s cancer therapy Vaximm may license its oral cancer therapy VXM01 in a deal worth up to $815M. Find out how OSR Holdings plans to turn this into a royalty-driven biotech play. byPallavi MadhirajuNovember 23, 2025